Delivery of multifactorial interventions by nurse and dietitian teams in a community setting to prevent diabetic complications: a quality-improvement report.
暂无分享,去创建一个
[1] M. Nahas. The global challenge of chronic kidney disease. , 2005 .
[2] K. Basu,et al. Drug coverage in Canada: who is at risk? , 2005, Health policy.
[3] F. McAlister,et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis , 2004, Canadian Medical Association Journal.
[4] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[5] G. Eknoyan,et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.
[6] F. Hutchison,et al. Prospective analysis of global costs for maintenance of patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[8] N. Freemantle,et al. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. , 2003, Diabetes care.
[9] Oluf Pedersen,et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.
[10] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[11] M. Massi-Benedetti. The Cost of Diabetes Type II in Europe The CODE-2 Study , 2002, Diabetologia.
[12] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] Paul Fenn,et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.
[14] H. Morrison,et al. End-stage renal disease in Canada: prevalence projections to 2005. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[15] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[16] B. Peterson,et al. Nurse Case Management To Improve Glycemic Control in Diabetic Patients in a Health Maintenance Organization , 1998, Annals of Internal Medicine.
[17] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[18] Philip D. Harvey,et al. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.
[19] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[20] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[21] J. Piercy,et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. , 1997, QJM : monthly journal of the Association of Physicians.
[22] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[23] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[24] C. Mogensen. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy , 1982, British medical journal.
[25] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[26] Clare Bradley,et al. Handbook of Psychology and Diabetes : A Guide to Psychological Measurement in Diabetes Research and Practice , 1994 .